Scientists Discover a New Way to Fight Heart Disease—By Targeting Cholesterol Where It Hides

Scientists at Clemson University and the Medical University of South Carolina have discovered a promising new approach to fighting heart disease by enhancing the body's natural ability to remove cholesterol buildup directly from artery walls. This breakthrough could offer hope for the millions of Americans whose cholesterol levels remain dangerously high despite taking traditional medications like statins.

How Does This New Approach Work?

The research focuses on two specific proteins—ABCA1 and ABCG1—that act like molecular cleanup crews within immune cells called macrophages. These proteins help transport cholesterol out of cells and hand it off to high-density lipoproteins (HDL), commonly known as "good cholesterol." Think of it as training your body's existing janitors to work more efficiently at removing the buildup that clogs your arteries.

"Many people take medications like statins to lower cholesterol, but those medications don't always stop heart disease from progressing," said Alexis "Stocko" Stamatikos, lead researcher and associate professor in Clemson's Department of Food, Nutrition and Packaging Sciences. "Our goal is to find better ways to remove cholesterol directly from the cells where it builds up."

Why Traditional Cholesterol Treatments Fall Short?

While statins effectively reduce cholesterol production in the liver, they don't address a critical problem: cholesterol that has already accumulated in arterial walls. This existing buildup can continue causing atherosclerosis—the hardening and narrowing of arteries that leads to heart attacks and strokes. The new research represents a shift from simply reducing cholesterol production to actively cleaning up existing deposits.

The approach targets macrophages, specialized immune cells that naturally "eat" cellular debris. By boosting the activity of ABCA1 and ABCG1 proteins within these cells, researchers hope to enhance the body's ability to clear cholesterol from where it causes the most damage—inside artery walls.

What Makes This Research Significant?

The implications extend far beyond the laboratory. According to the U.S. Centers for Disease Control and Prevention, more than 86 million adults in the United States have cholesterol levels of 200 mg/dL or higher, well above the optimal level of 150 mg/dL. High cholesterol often produces no symptoms, making it a silent threat to cardiovascular health.

Several factors contribute to elevated cholesterol levels and make this research particularly relevant:

• Dietary Factors: Poor eating habits and lack of exercise significantly impact cholesterol management
• Genetic Predisposition: Some individuals struggle with cholesterol control regardless of lifestyle changes
• Medical Conditions: Underlying issues like diabetes can complicate traditional cholesterol treatments
• Medication Limitations: Current treatments don't always prevent disease progression in all patients

"This research could pave the way for therapies that work inside artery walls, addressing the problem at its source," said Stamatikos. The potential for clinical applications appears promising, though the research remains in early stages.

The ABCA1 and ABCG1 proteins belong to a family of transporters that facilitate cholesterol movement out of cells. When activated, they assist in transferring cholesterol to apoAI, a primary protein in HDL that plays key roles in cholesterol transport and helps remove excess cholesterol from body tissues for liver processing.

"It's a step forward in understanding how the body may defend itself against atherosclerosis and what may be done for future atherosclerosis therapies to become more effective," Stamatikos explained. Future studies will focus on safely and effectively activating these proteins in living organisms, with the ultimate goal of developing therapies that not only lower cholesterol levels but prevent the vascular damage that high cholesterol causes.